Table 2.

Efficacy of UPA in U-ACHIEVE Phase 2 Trial

Primary and Secondary Endpoints at Week 8, N (%), p-value	UPA 7.5 mg, N = 47	UPA 15 mg, N = 49	UPA 30 mg, N = 52	UPA 45 mg, N = 56	PBO, N = 46
Clinical remission	4 (8.5), p = 0.052	7 (14.3), p = 0.013	7 (13.5), p = 0.011	11 (19.6), p = 0.002	0 (0)
Endoscopic improvement	7 (14.9), p = 0.033	15 (30.6), p < 0.001	14 (26.9), p < 0.001	20 (35.7), p < 0.001	1 (2.2)
Clinical response	14 (29.8), p = 0.046	22 (44.9), p < 0.001	23 (44.2), p < 0.001	28 (50), p < 0.001	6 (13)
Endoscopic remission	3 (6.4), p = 0.101	2 (4.1), p = 0.212	5 (9.6), p = 0.015	10 (17.9), p = 0.004	0
Histologic improvement	15 (31.9), p = 0.003	25 (51), p < 0.001	23 (44.2), p < 0.001	27 (48.2), p < 0.001	3 (6.5)

Abbreviations: UPA, upadacitinib; PBO, placebo.